Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05473923 | PTCs-based Precision Treatment Strategy on Recurrent High-grade Gliomas | active not recruiting | Early Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06791681 | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 24 | Chunrui LiOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06713148 |
| Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors |
| not yet recruiting |
| Early Phase 1 |
| 42 |
| Fudan UniversityOTHER |
| 0 |
| Feb 6, 2025 |
| clinicaltrials |
| NCT06718946 | Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06276686 | Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer | recruiting | Early Phase 1 | 30 | University of HullOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06806189 | Lipiodal Injection Technique for Free Flap Sparing Adjuvant RT Planning in HNC | not yet recruiting | Early Phase 1 | 10 | Western University, CanadaOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02872025 | Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | active not recruiting | Early Phase 1 | 42 | Laura EssermanOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06793241 | Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06307600 | The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia | recruiting | Early Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. | not yet recruiting | Early Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06756334 | Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis | recruiting | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06752473 | KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 10 | Kousai Bio Co., Ltd.OTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | recruiting | Early Phase 1 | 30 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | recruiting | Early Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06734572 | 18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study | recruiting | Early Phase 1 | 5 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735508 | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | not yet recruiting | Early Phase 1 | 40 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06716164 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06652243 | Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma(SN301A) | recruiting | Early Phase 1 | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06696833 | Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | recruiting | Early Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06697665 | An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693973 | An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Early Phase 1 | 13 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06695689 | An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06690476 | Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma | recruiting | Early Phase 1 | 74 | Peking UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06438250 | 68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies | recruiting | Early Phase 1 | 5 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06688188 | 68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study | recruiting | Early Phase 1 | 5 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06688305 | 68Ga-NI-FAPI PET/CT: First-in-human Study | recruiting | Early Phase 1 | 40 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06685653 | Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | not yet recruiting | Early Phase 1 | 65 | Nanjing Tianyinshan HospitalOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT05141474 | Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors(NEXTGENTIL-ACT) | recruiting | Early Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06635434 | An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients | active not recruiting | Early Phase 1 | 16 | ALTality, Inc.INDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06659653 | Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. | recruiting | Early Phase 1 | 18 | Tan JieOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06642025 | EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 9 | Zhimin ZhaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633354 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06515626 | Genetically Modified T Cells Treating Malignant Tumors | recruiting | Early Phase 1 | 100 | Yi ZhangOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06612580 | 68Ga-AAZTA-NI-093 PET/CT: First-in-human Study | recruiting | Early Phase 1 | 10 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06613152 | HS-IT201 Injection in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 9 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT05996432 | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | recruiting | Early Phase 1 | 48 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05831033 | Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2025source: clinicaltrials